{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:48:56Z","timestamp":1783648136810,"version":"3.55.0"},"reference-count":243,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2023MS359"],"award-info":[{"award-number":["2023MS359"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108948","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T23:04:09Z","timestamp":1756767849000},"page":"108948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies"],"prefix":"10.1016","volume":"165","author":[{"given":"Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13058-023-01622-7","article-title":"RET signaling in breast cancer therapeutic resistance and metastasis","volume":"25","author":"Pecar","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0015","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108948_bb0020","doi-asserted-by":"crossref","first-page":"7857","DOI":"10.2147\/OTT.S171665","article-title":"Targeted therapy for RET-rearranged non-small cell lung Cancer: clinical development and future directions","volume":"12","author":"Ackermann","year":"2019","journal-title":"Onco. Targets. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0030","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0035","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2025.108948_bb0040","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3389\/fphys.2018.01873","article-title":"GDNF and the RET receptor in Cancer: new insights and therapeutic potential","volume":"9","author":"Mulligan","year":"2018","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/1759-7714.12603","article-title":"Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases","volume":"9","author":"Tan","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bioorg.2025.108948_bb0050","article-title":"Metabolism, clinical activity of selpercatinib in RET-mutant pheochromocytoma","author":"Deschler-Baier","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-020-01557-3","article-title":"Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer","volume":"39","author":"Guan","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0060","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1007\/s00432-022-04496-y","article-title":"Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma","volume":"149","author":"Schrenk","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0065","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fonc.2020.01642","article-title":"Receptor tyrosine kinases in osteosarcoma treatment: which is the key target?","volume":"10","author":"Tian","year":"2020","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0070","doi-asserted-by":"crossref","first-page":"966","DOI":"10.6004\/jnccn.2022.7030","article-title":"Response to Selpercatinib in a patient with recurrent glioblastoma and RET amplification","volume":"20","author":"Czech","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0075","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41416-020-0905-8","article-title":"Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS\/MAPK, PI3K\/Akt\/mTOR and Fos\/Jun pathways","volume":"123","author":"Subramonian","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"59","key":"10.1016\/j.bioorg.2025.108948_bb0080","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.18632\/oncotarget.27259","article-title":"The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo","volume":"10","author":"Flynn","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.108948_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1134151","article-title":"Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report","volume":"13","author":"Arora","year":"2023","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0090","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Metabolism, consensus: guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108948_bb0095","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa012915","article-title":"European multiple endocrine neoplasia study, early malignant progression of hereditary medullary thyroid cancer, N","volume":"349","author":"Machens","year":"2003","journal-title":"Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-10-0333","article-title":"multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes","volume":"163","author":"Romei","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fgene.2019.00924","article-title":"Functional studies on novel RET mutations and their implications for genetic counseling for Hirschsprung disease","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0110","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0115","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/jc.2014-4153","article-title":"RET fusion as a novel driver of medullary thyroid carcinoma","volume":"100","author":"Grubbs","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.108948_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung Cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0130","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0135","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0140","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11684-023-0985-y","article-title":"Progress and challenges in RET-targeted cancer therapy","volume":"17","author":"Hu","year":"2023","journal-title":"Front. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.bioorg.2025.108948_bb0150","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80599-8","article-title":"Imatinib: a selective tyrosine kinase inhibitor","volume":"38","author":"Manley","year":"2002","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0155","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-Centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"issue":"29","key":"10.1016\/j.bioorg.2025.108948_bb0160","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(20)30202-3","article-title":"Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-Centre, phase 2 trial","volume":"21","author":"Apolo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0170","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1158\/1535-7163.MCT-07-2422","article-title":"Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib\/tipifarnib","volume":"7","author":"Hong","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"9940","key":"10.1016\/j.bioorg.2025.108948_bb0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"D. investigators, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.108948_bb0185","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/13543784.2021.1972971","article-title":"Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer","volume":"30","author":"Ferrari","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"9863","key":"10.1016\/j.bioorg.2025.108948_bb0195","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.bioorg.2025.108948_bb0200","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"G.S. investigators, Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.bioorg.2025.108948_bb0205","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0215","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14740338.2018.1535592","article-title":"The safety of apatinib for the treatment of gastric cancer","volume":"17","author":"Geng","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0220","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.annonc.2022.04.009","article-title":"ESMO clinical practice guideline update on the use of systemic therapy in advanced thyroid cancer","volume":"33","author":"Filetti","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0225","article-title":"Resistance to RET targeted therapy in thyroid Cancer: molecular basis and overcoming strategies","volume":"105","author":"San Roman-Gil","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108948_bb0230","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1111\/bph.14395","article-title":"Drug resistance profiles of mutations in the RET kinase domain","volume":"175","author":"Liu","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0235","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","article-title":"A secondary RET mutation in the activation loop conferring resistance to vandetanib","volume":"9","author":"Nakaoku","year":"2018","journal-title":"Nat. Commun."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108948_bb0240","doi-asserted-by":"crossref","first-page":"6102","DOI":"10.1158\/1078-0432.CCR-20-1587","article-title":"Progresses toward precision medicine in RET-altered solid tumors","volume":"26","author":"Belli","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0245","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S2213-2600(16)30322-8","article-title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","volume":"5","author":"Yoh","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0255","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A phase I\/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2019","journal-title":"Cancer Discov."},{"issue":"29","key":"10.1016\/j.bioorg.2025.108948_bb0260","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188949","article-title":"Ponatinib: An update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1501290","article-title":"TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1","volume":"2","author":"Hossain","year":"2016","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0275","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2169\/internalmedicine.7472-21","article-title":"Severe skin toxicity caused by sequential anti-PD-1 antibody and Alectinib in non-small-cell lung Cancer: A report of two cases and a literature review","volume":"61","author":"Nishiyama","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.bioorg.2025.108948_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1024365","article-title":"Case report: recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC","volume":"12","author":"An","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0285","article-title":"Psychiatric adverse reactions to non-selective RET multi-kinase inhibitors: a large-scale pharmacovigilance analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jfo.2020.06.053","article-title":"Corneal perforation with tyrosine kinase inhibitor chemotherapy: REGORAFENIB","volume":"44","author":"Lanfant","year":"2021","journal-title":"J. Fr. Ophtalmol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nbt0114-9a","article-title":"FDA halts then allows sales of Ariad's leukemia medication","volume":"32","author":"Senior","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb0300","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1158\/1535-7163.MCT-16-0258","article-title":"Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma","volume":"15","author":"Huang","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108948_bb0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00189","article-title":"Emergence and targeting of acquired and hereditary resistance to multikinase RET inhibition in patients with RET-altered Cancer","volume":"3","author":"Wirth","year":"2019","journal-title":"JCO Precis. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0310","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0315","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.cell.2023.02.040","article-title":"Selpercatinib: first approved selective RET inhibitor","volume":"186","author":"Oliveira","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0320","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0325","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid Cancer: updates and challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bioorg.2025.108948_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108344","article-title":"RET aberrant cancers and RET inhibitor therapies: current state-of-the-art and future perspectives","volume":"242","author":"Addeo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.108948_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0340","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108948_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953013","article-title":"Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020","volume":"12","author":"Kooijman","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0350","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.beem.2017.04.013","article-title":"The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer","volume":"31","author":"De Falco","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0355","first-page":"1519","article-title":"Human ret proto-oncogene mapped to chromosome 10q11.2","volume":"4","author":"Ishizaka","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108948_bb0360","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47650","article-title":"Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands","volume":"8","author":"Li","year":"2019","journal-title":"Elife"},{"issue":"16","key":"10.1016\/j.bioorg.2025.108948_bb0365","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1074\/jbc.M110.195461","article-title":"RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons","volume":"286","author":"Cabrera","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0370","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1210\/jc.2010-0771","article-title":"RET-mediated cell adhesion and migration require multiple integrin subunits","volume":"95","author":"Cockburn","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0375","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0092-8674(03)00435-5","article-title":"The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands","volume":"113","author":"Paratcha","year":"2003","journal-title":"Cell"},{"issue":"38","key":"10.1016\/j.bioorg.2025.108948_bb0380","doi-asserted-by":"crossref","first-page":"35808","DOI":"10.1074\/jbc.M104968200","article-title":"Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site","volume":"276","author":"Anders","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0385","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.celrep.2014.08.040","article-title":"RET recognition of GDNF-GFRalpha1 ligand by a composite binding site promotes membrane-proximal self-association","volume":"8","author":"Goodman","year":"2014","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0390","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"53","author":"Plaza-Menacho","year":"2014","journal-title":"Mol. Cell"},{"issue":"27","key":"10.1016\/j.bioorg.2025.108948_bb0395","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1074\/jbc.RA119.007682","article-title":"Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib","volume":"294","author":"Terzyan","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0400","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1359-6101(01)00012-0","article-title":"The GDNF\/RET signaling pathway and human diseases","volume":"12","author":"Takahashi","year":"2001","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0405","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET proto-oncogene in Cancer and development","volume":"3","author":"Takahashi","year":"2020","journal-title":"JMA J"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0410","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0304-3835(03)00456-7","article-title":"RET and neuroendocrine tumors","volume":"204","author":"Ichihara","year":"2004","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0415","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","article-title":"GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors","volume":"73","author":"Morandi","year":"2013","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.bioorg.2025.108948_bb0420","doi-asserted-by":"crossref","first-page":"11732","DOI":"10.1158\/0008-5472.CAN-07-2343","article-title":"A role for glial cell\u2013derived neurotrophic factor\u2013induced expression by inflammatory cytokines and ret\/gfr\u03b11 receptor up-regulation in breast cancer","volume":"67","author":"Esseghir","year":"2007","journal-title":"Cancer Res."},{"issue":"33","key":"10.1016\/j.bioorg.2025.108948_bb0425","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/onc.2010.209","article-title":"Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance","volume":"29","author":"Plaza-Menacho","year":"2010","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0430","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/emmm.201302625","article-title":"Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells","volume":"5","author":"Gattelli","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10911-020-09445-4","article-title":"Ret receptor has distinct alterations and functions in breast Cancer","volume":"25","author":"Gattelli","year":"2020","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0440","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/147323000803600406","article-title":"The relationship between over-expression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer","volume":"36","author":"Zeng","year":"2008","journal-title":"J. Int. Med. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0445","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.surg.2005.07.007","article-title":"Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers","volume":"138","author":"Ito","year":"2005","journal-title":"Surgery"},{"issue":"23","key":"10.1016\/j.bioorg.2025.108948_bb0450","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/onc.2016.483","article-title":"Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma","volume":"36","author":"Amit","year":"2017","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.bioorg.2025.108948_bb0455","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-17-0528","article-title":"RET signaling in prostate Cancer","volume":"23","author":"Ban","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0460","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.bioorg.2025.108948_bb0465","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.28661","article-title":"RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma","volume":"120","author":"Krampitz","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0475","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/JTO.0000000000000135","article-title":"Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma","volume":"9","author":"Mizukami","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0480","doi-asserted-by":"crossref","first-page":"E991","DOI":"10.1210\/jc.2010-2381","article-title":"The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells","volume":"96","author":"Verbeek","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0485","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cas.12175","article-title":"Identification of a lung adenocarcinoma cell line with CCDC 6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo","volume":"104","author":"Suzuki","year":"2013","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0490","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0495","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0500","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28222","article-title":"Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the pediatric preclinical testing consortium","volume":"67","author":"Harrison","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0505","first-page":"18","article-title":"Effect of Lenvatinib on a patient with medullary thyroid carcinoma liver metastasis caused by multiple endocrine neoplasia type 2A","volume":"45","author":"Sato","year":"2020","journal-title":"Tokai J. Exp. Clin. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0510","doi-asserted-by":"crossref","first-page":"e3027","DOI":"10.1210\/clinem\/dgab196","article-title":"Long-term results of a phase II trial of Apatinib for progressive radioiodine refractory differentiated thyroid Cancer","volume":"106","author":"Lin","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0515","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2021.6268","article-title":"Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid Cancer: the REALITY randomized clinical trial","volume":"8","author":"Lin","year":"2022","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-023-02841-7","article-title":"Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0525","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12885-024-12340-4","article-title":"Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric\/gastroesophageal tumors: a systematic review and meta-analysis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.bioorg.2025.108948_bb0530","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0535","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1078-0432.CCR-1100-03","article-title":"Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy","volume":"10","author":"Ciardiello","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0540","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1208\/s12249-024-02869-9","article-title":"Advanced delivery strategies of Nintedanib for lung disorders and beyond: A comprehensive review","volume":"25","author":"Thakkar","year":"2024","journal-title":"AAPS PharmSciTech"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0545","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of Nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108948_bb0550","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1242\/dev.128.20.3963","article-title":"RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons","volume":"128","author":"Enomoto","year":"2001","journal-title":"Development"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0555","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/path.1711720305","article-title":"Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin","volume":"172","author":"Nakamura","year":"1994","journal-title":"J. Pathol."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108948_bb0560","first-page":"5399","article-title":"Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase","volume":"57","author":"Marshall","year":"1997","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0565","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.18632\/oncotarget.1883","article-title":"Activated Alk triggers prolonged neurogenesis and ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma","volume":"5","author":"Cazes","year":"2014","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.bioorg.2025.108948_bb0570","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0575","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/carcin\/bgz184","article-title":"RET oma: a cancer subtype with a shared driver oncogene","volume":"41","author":"Kohno","year":"2020","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0580","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb0585","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.celrep.2017.08.037","article-title":"KIF5B-RET Oncoprotein signals through a multi-kinase signaling hub","volume":"20","author":"Das","year":"2017","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0590","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non-small cell lung cancer, Version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"36","key":"10.1016\/j.bioorg.2025.108948_bb0595","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41574-019-0307-2","article-title":"Therapeutic breakthroughs for metastatic thyroid cancer","volume":"16","author":"Tiedje","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb0605","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N","volume":"372","author":"Schlumberger","year":"2015","journal-title":"Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0610","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clon.2017.02.009","article-title":"Targeted therapy in thyroid Cancer: state of the art","volume":"29","author":"Valerio","year":"2017","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"15","key":"10.1016\/j.bioorg.2025.108948_bb0615","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1158\/1078-0432.CCR-13-0071","article-title":"Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma","volume":"19","author":"Fox","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0620","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s40618-020-01272-y","article-title":"Proteinuria is a late-onset adverse event in patients treated with cabozantinib","volume":"44","author":"Cappagli","year":"2021","journal-title":"J. Endocrinol. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0625","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with vascular endothelial growth factor inhibitor therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis Oncol."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108948_bb0630","doi-asserted-by":"crossref","first-page":"11747","DOI":"10.1021\/acs.jmedchem.0c02167","article-title":"Targeting rearranged during transfection in Cancer: A perspective on small-molecule inhibitors and their clinical development","volume":"64","author":"Saha","year":"2021","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0635","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1530\/ERC-13-0085","article-title":"Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells","volume":"20","author":"Gild","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"issue":"14","key":"10.1016\/j.bioorg.2025.108948_bb0640","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108948_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103882","article-title":"Targeting RET alterations in cancer: recent progress and future directions","volume":"181","author":"Shabbir","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108948_bb0650","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of Selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108948_bb0655","article-title":"Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases","volume":"4","author":"Andreev-Drakhlin","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb0660","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0665","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0670","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108948_bb0675","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","article-title":"Pralsetinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"15 suppl","key":"10.1016\/j.bioorg.2025.108948_bb0680","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2019.37.15_suppl.9008","article-title":"Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-fusion+ non small cell lung cancer","volume":"37","author":"Gainor","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0685","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114862","article-title":"1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions","volume":"244","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0695","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/EJE-22-0312","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives","volume":"187","author":"Saltiki","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0700","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0705","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114995","article-title":"Molecular mechanisms of the tyrosine kinase inhibitor pralsetinib activity in in-vitro models of medullary thyroid carcinoma: aberrant activation of the HH-Gli signaling pathway in acquired resistance","volume":"164","author":"Trocchianesi","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0715","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00894-022-05429-9","article-title":"Insights into pralsetinib resistance to the non-gatekeeper RET kinase G810C mutation through molecular dynamics simulations","volume":"29","author":"Cao","year":"2023","journal-title":"J. Mol. Model."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0720","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line Osimertinib in EGFR-mutant lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108948_bb0725","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","article-title":"Amplification of wild-type KRAS imparts resistance to Crizotinib in MET exon 14 mutant non-small cell lung Cancer","volume":"24","author":"Bahcall","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108948_bb0730","article-title":"Pharmacotherapy, Therapeutic strategy using novel RET\/YES1 dual-target inhibitor in lung cancer","volume":"171","author":"Choi","year":"2024"},{"key":"10.1016\/j.bioorg.2025.108948_bb0735","series-title":"Signaling, Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition","first-page":"67","volume":"19","author":"Ortiz","year":"2021"},{"key":"10.1016\/j.bioorg.2025.108948_bb0740","series-title":"Bioscience, Current knowledge and challenges associated with targeted delivery of neurotrophic factors into the central nervous system: focus on available approaches","first-page":"1","volume":"11","author":"Bahlakeh","year":"2021"},{"key":"10.1016\/j.bioorg.2025.108948_bb0745","series-title":"Src tyrosyl phosphorylates cortactin in response to prolactin","first-page":"644","volume":"463","author":"Hammer","year":"2015"},{"key":"10.1016\/j.bioorg.2025.108948_bb0750","series-title":"The journal of the American Society of Hematology, Src family kinases: at the forefront of platelet activation","first-page":"2013","volume":"124","author":"Senis","year":"2014"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0755","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021"},{"key":"10.1016\/j.bioorg.2025.108948_bb0760","series-title":"Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy","volume":"8","author":"Poh","year":"2022"},{"key":"10.1016\/j.bioorg.2025.108948_bb0765","series-title":"Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma","first-page":"4223","volume":"75","author":"Yu","year":"2018"},{"key":"10.1016\/j.bioorg.2025.108948_bb0770","series-title":"FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development","first-page":"312","volume":"111","author":"Kiyoi","year":"2020"},{"key":"10.1016\/j.bioorg.2025.108948_bb0775","series-title":"RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia","first-page":"2189","volume":"32","author":"Rudat","year":"2018"},{"key":"10.1016\/j.bioorg.2025.108948_bb0780","series-title":"The Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and na\u00efve RET-Driven cancer Models","author":"Drilon","year":"2020"},{"key":"10.1016\/j.bioorg.2025.108948_bb0785","doi-asserted-by":"crossref","first-page":"v190","DOI":"10.1093\/annonc\/mdz244.068","article-title":"TPX-0046 is a novel and potent RET\/SRC inhibitor for RET-driven cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0790","doi-asserted-by":"crossref","first-page":"16103","DOI":"10.1038\/s41598-021-95612-4","article-title":"Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases","volume":"11","author":"Moccia","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108948_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117749","article-title":"Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET\/TRKA inhibitors","volume":"106","author":"Acharya","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0800","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: Entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0805","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40265-018-1044-x","article-title":"Larotrectinib: first global approval","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.108948_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116534","article-title":"How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors","volume":"53","author":"Mondal","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0815","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/07391102.2023.2204351","article-title":"An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review","volume":"42","author":"Dhiwar","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0820","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/jm700956r","article-title":"Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships","volume":"51","author":"Vanotti","year":"2008","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108948_bb0825","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1021\/jm300801u","article-title":"Design, synthesis, and structure-activity relationships of highly potent 5-HT(3) receptor ligands","volume":"55","author":"Verheij","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb0830","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/acsmedchemlett.9b00243","article-title":"Dual inhibition of TAF1 and BET Bromodomains from the BI-2536 kinase inhibitor scaffold","volume":"10","author":"Remillard","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0835","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acsomega.9b03223","article-title":"Nicotinamide-Ponatinib analogues as potent anti-CML and anti-AML compounds","volume":"5","author":"Larocque","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.108948_bb0840","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1039\/D5MD00245A","article-title":"Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy","author":"Khatri","year":"2025","journal-title":"RSC Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb0845","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1158\/1535-7163.MCT-22-0629","article-title":"Targeting RET solvent-front mutants with Alkynyl nicotinamide-based inhibitors","volume":"22","author":"Khatri","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0850","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1021\/acsmedchemlett.0c00015","article-title":"Efficacy and tolerability of Pyrazolo[1,5-a]pyrimidine RET kinase inhibitors for the treatment of lung adenocarcinoma","volume":"11","author":"Mathison","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0855","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2015.04.004","article-title":"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases","volume":"89","author":"Subbiah","year":"2015","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0860","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jtho.2016.08.126","article-title":"Clinical activity of Alectinib in advanced RET-rearranged non-small cell lung Cancer","volume":"11","author":"Lin","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.584894","article-title":"Identification of a new potential SARS-COV-2 RNA-dependent RNA polymerase inhibitor via combining fragment-based drug design, Docking, Molecular Dynamics, and MM-PBSA Calculations","volume":"8","author":"El Hassab","year":"2020","journal-title":"Front. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108948_bb0870","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.1039\/D1RA09339H","article-title":"Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics","volume":"12","author":"Anjum","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.108948_bb0875","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fmolb.2020.00180","article-title":"Application of fragment-based drug discovery to versatile targets","volume":"7","author":"Li","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bioorg.2025.108948_bb0880","first-page":"114","article-title":"Design of ALK inhibitors for non-small cell lung Cancer\u2013A fragment based approach, Indian J. Pharm","volume":"54","author":"Jain","year":"2020","journal-title":"Educ. Res."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0885","first-page":"2423","article-title":"Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations, Saudi","volume":"28","author":"Jairajpuri","year":"2021","journal-title":"Aust. J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0890","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.3390\/pharmaceutics13122157","article-title":"Identification of Phytoconstituents as potent inhibitors of casein Kinase-1 alpha using virtual screening and molecular dynamics simulations","volume":"13","author":"Shafie","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0895","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1039\/D1RA07328A","article-title":"Investigating natural compounds against oncogenic RET tyrosine kinase using pharmacoinformatic approaches for cancer therapeutics","volume":"12","author":"Parate","year":"2021","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb0900","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3233\/JAD-230698","article-title":"Structure-based identification of natural compounds as potential RET-kinase inhibitors for therapeutic targeting of neurodegenerative diseases","volume":"95","author":"Hasan","year":"2023","journal-title":"J Alzheimer's Dis"},{"issue":"50","key":"10.1016\/j.bioorg.2025.108948_bb0905","doi-asserted-by":"crossref","first-page":"34640","DOI":"10.1021\/acsomega.3c03578","article-title":"Correction to \u201cdesign and synthesis of novel Thieno [3, 2-c] quinoline compounds with Antiproliferative activity on RET-dependent medullary thyroid Cancer cells\u201d","volume":"8","author":"La Monica","year":"2023","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0910","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1021\/acschembio.9b00407","article-title":"Leveraging Atropisomerism to obtain a selective inhibitor of RET kinase with secondary activities toward EGFR mutants","volume":"14","author":"Toenjes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.108948_bb0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115751","article-title":"Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy","volume":"216","author":"Steen","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb0920","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201900053","article-title":"Quinazoline based 1,3,5-triazine derivatives as cancer inhibitors by impeding the phosphorylated RET tyrosine kinase pathway: design, synthesis, docking, and QSAR study","volume":"352","author":"Pathak","year":"2019","journal-title":"Arch Pharm (Weinheim)"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb0925","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/molecules26030691","article-title":"Molecular modelling studies on Pyrazole derivatives for the Design of Potent Rearranged during transfection kinase inhibitors","volume":"26","author":"Bhujbal","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108948_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128149","article-title":"Discovery and optimization of selective RET inhibitors via scaffold hopping","volume":"47","author":"Luo","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb0935","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1021\/acsmedchemlett.1c00450","article-title":"Antitarget selectivity and tolerability of novel Pyrrolo[2,3-d]pyrimidine RET inhibitors","volume":"12","author":"Mathison","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108948_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112755","article-title":"Discovery of 4-methyl-N-(4-((4-methylpiperazin- 1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-oxy)benzamide as a potent inhibitor of RET and its gatekeeper mutant","volume":"207","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"5486","key":"10.1016\/j.bioorg.2025.108948_bb0945","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb0950","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb0955","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/1535-7163.MCT-21-0127","article-title":"The novel RET inhibitor SYHA1815 inhibits RET-driven cancers and overcomes gatekeeper mutations by inducing G(1) cell-cycle arrest through c-Myc downregulation","volume":"20","author":"Jiang","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb0960","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cmdc.202100013","article-title":"Pyrazoloadenine inhibitors of the RET lung Cancer Oncoprotein discovered by a fragment optimization approach","volume":"16","author":"Saha","year":"2021","journal-title":"Chemmedchem"},{"key":"10.1016\/j.bioorg.2025.108948_bb0965","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejmech.2018.08.023","article-title":"Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes","volume":"157","author":"Pathania","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108948_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112691","article-title":"Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: design, synthesis and biological evaluation","volume":"206","author":"Lakkaniga","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb0975","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/acs.jmedchem.1c01280","article-title":"Discovery of N-Trisubstituted pyrimidine derivatives as type I RET and RET gatekeeper mutant inhibitors with a novel kinase binding pose","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb0980","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/ph14010038","article-title":"Characterization of LDD-2633 as a novel RET kinase inhibitor with anti-tumor effects in thyroid Cancer","volume":"14","author":"Lee","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bioorg.2025.108948_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115237","article-title":"Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors","volume":"251","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108948_bb0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103052","article-title":"Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma","volume":"90","author":"Wang","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb0995","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1000","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb1005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/cas.16069","article-title":"Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia","volume":"115","author":"Frett","year":"2024","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb1010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-021-00867-8","article-title":"Therapeutic advances in the Management of Patients with advanced RET fusion-positive non-small cell lung Cancer","volume":"22","author":"Sun","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3349\/ymj.2017.58.1.9","article-title":"EGF induced RET inhibitor resistance in CCDC6-RET lung Cancer cells","volume":"58","author":"Chang","year":"2017","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bioorg.2025.108948_bb1020","series-title":"MDM2 Amplification (Amp) to Mediate Cabozantinib Resistance in Patients (Pts) with Advanced RET-Rearranged Lung Cancers","author":"Somwar","year":"2016"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb1030","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1083\/jcb.149.7.1419","article-title":"Coupling of Gab1 to c-met, Grb2, and Shp2 mediates biological responses","volume":"149","author":"Schaeper","year":"2000","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108948_bb1035","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/MCB.01286-08","article-title":"Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the met receptor","volume":"29","author":"Paliouras","year":"2009","journal-title":"Mol. Cell. Biol."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108948_bb1040","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","article-title":"The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase","volume":"20","author":"Maroun","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb1045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/CAD.0000000000001291","article-title":"Poor response to selpercatinib plus crizotinib in a rearranged during transfection fusion-positive patient with acquired selpercatinib-resistant MNNG HOS transforming amplification: a case report","volume":"33","author":"Meng","year":"2022","journal-title":"Anticancer Drugs"},{"issue":"24","key":"10.1016\/j.bioorg.2025.108948_bb1050","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and -independent resistance mechanisms to Osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb1055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.canlet.2016.07.021","article-title":"Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment","volume":"380","author":"Shi","year":"2016","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1060","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung Cancer by combining Selpercatinib with Crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.bioorg.2025.108948_bb1065","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb1070","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-18-2814","article-title":"Capmatinib (INC280) is active against models of non-small cell lung Cancer and other Cancer types with defined mechanisms of MET activation","volume":"25","author":"Baltschukat","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108948_bb1075","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung Cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.108948_bb1080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1264231","article-title":"Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: case report","volume":"13","author":"Leite","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108948_bb1085","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210390","article-title":"Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer","volume":"219","author":"Raman","year":"2022","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.17305\/bjbms.2018.2756","article-title":"The role of the hedgehog signaling pathway in cancer: A comprehensive review","volume":"18","author":"Skoda","year":"2018","journal-title":"Bosn. J. Basic Med. Sci."},{"key":"10.1016\/j.bioorg.2025.108948_bb1095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1476-4598-12-66","article-title":"Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner","volume":"12","author":"Lei","year":"2013","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb1100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ijrobp.2014.06.065","article-title":"Reciprocal regulation of hypoxia-inducible factor 2alpha and GLI1 expression associated with the radioresistance of renal cell carcinoma","volume":"90","author":"Zhou","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb1105","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s13277-014-2948-z","article-title":"Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer","volume":"36","author":"Lei","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bioorg.2025.108948_bb1110","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fgene.2019.00556","article-title":"Non-canonical hedgehog signaling pathway in Cancer: activation of GLI transcription factors beyond smoothened","volume":"10","author":"Pietrobono","year":"2019","journal-title":"Front. Genet."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb1115","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/ijms19041098","article-title":"Hedgehog signals mediate anti-Cancer drug resistance in three-dimensional primary colorectal Cancer organoid culture","volume":"19","author":"Usui","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108948_bb1120","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1089\/thy.2012.0474","article-title":"Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway","volume":"23","author":"Bohinc","year":"2013","journal-title":"Thyroid"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108948_bb1125","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.0609699104","article-title":"Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists","volume":"104","author":"Lauth","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108948_bb1130","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb1135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40264-018-0777-5","article-title":"Safety and tolerability of sonic hedgehog pathway inhibitors in Cancer","volume":"42","author":"Carpenter","year":"2019","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1172\/JCI42874","article-title":"Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking hedgehog\/GLI pathway","volume":"121","author":"Beauchamp","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb1145","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","article-title":"YAP\/TAZ upstream signals and downstream responses","volume":"20","author":"Totaro","year":"2018","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108948_bb1150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1139\/bcb-2019-0354","article-title":"YAP confers resistance to vandetanib in medullary thyroid cancer","volume":"98","author":"Wang","year":"2020","journal-title":"Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108948_bb1155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to Cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108948_bb1160","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1101\/gad.192856.112","article-title":"Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP","volume":"26","author":"Liu-Chittenden","year":"2012","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108948_bb1165","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/ijms23073497","article-title":"Toward a treatment of Cancer: design and in vitro\/in vivo evaluation of uncharged Pyrazoline derivatives as a series of novel SHP2 inhibitors","volume":"23","author":"Dai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb1170","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108948_bb1175","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of Cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108948_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216517","article-title":"JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK\/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers","volume":"582","author":"Lu","year":"2024","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108948_bb1185","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb1190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.celrep.2013.12.035","article-title":"Assessing PIK3CA and PTEN in early-phase trials with PI3K\/AKT\/mTOR inhibitors","volume":"6","author":"Janku","year":"2014","journal-title":"Cell Rep."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108948_bb1195","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108948_bb1200","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100079","article-title":"Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study","volume":"6","author":"Cascone","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108948_bb1210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41392-024-02006-9","article-title":"First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108948_bb1215","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:26:03Z","timestamp":1760559963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":243,"alternative-id":["S0045206825008284"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108948","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108948"}}